Small Molecule · SYT-510
SYT-510
Oral, first-in-class selective endocannabinoid reuptake inhibitor (SERI) developed by Synendos Therapeutics, a Basel company spun out of the University of Bern. Per the company, SERIs mildly and selectively raise endogenous cannabinoid levels by inhibiting a newly identified target in the endocannabinoid system; Synendos's ECNP 2026 pharmacology poster identifies that target as the endocannabinoid membrane transporter ACSL4 isoform 2 and reports reversible inhibition of anandamide and 2-AG uptake with selectivity over CB1, CB2, FAAH, MAGL, ABHD6 and ABHD12. An EMA-authorised first-in-human single-ascending-dose study and a UK multiple-ascending-dose study in healthy volunteers were completed; the company reported no drug-related safety concerns, CNS exposure at the anticipated pharmacological levels, and an EEG effect consistent with anxiolytic medicines. A Phase 2a single-dose crossover experimental-medicine study in generalized anxiety disorder began dosing in 2026 with preliminary data guided for early 2027. Chemical structure has not been disclosed.
Also known as: SYT-510, SYT510, SYT 510
Key facts
- Modality
- Small molecule
- Mechanism
- ACSL4 inhibitor
- Highest phase
- Phase 2
- Lead indication
- Generalized anxiety disorder
- Developer
- Synendos Therapeutics AG
- Trials
- 2 tracked · 1 recruiting · 1 sites
- Next catalyst
- Early 2027 — Topline data (Generalized anxiety disorder)
Mechanism of action#
Selective endocannabinoid reuptake inhibitor (SERI). Synendos describes SYT-510 as a first-in-class inhibitor of a newly identified drug target in the endocannabinoid system that mildly and selectively increases endogenous cannabinoid levels with a self-limiting mode of action. The sponsor's ECNP 2026 preclinical characterization reports that SYT-510 binds the endocannabinoid membrane transporter ACSL4 isoform 2 and selectively, reversibly inhibits cellular uptake of anandamide (AEA) and 2-arachidonoylglycerol (2-AG), is selective against CB1R, CB2R, FAAH, MAGL, ABHD6 and ABHD12 and a CNS receptor/ion-channel panel, elicits CB1-mediated, ACSL4-dependent short-term synaptic plasticity in brain slices, and is active in rodent anxiety and compulsive-behaviour models without sedation or tolerance. In healthy volunteers, 14 days of dosing increased plasma 2-AG and produced a dose-dependent increase in EEG beta power. The clinical hypothesis is that raising endogenous cannabinoid tone produces anxiolysis without the cognitive impairment, sedation and abuse liability of direct CB1 agonists.
| Target | Action | Affinity |
|---|---|---|
| ACSL4primaryACSL4 | Inhibitor | —ⓘ |
Formulations#
| Formulation | Route | Regimen | Pharmacokinetics |
|---|---|---|---|
| SYT-510 oral formulation Phase 2a (NCT07478744): a single oral dose in the morning with liquid, versus matching placebo, in a two-way crossover. Phase 1 (NCT06670950): two oral formulations (A and B) compared for relative bioavailability fasted, formulation A fed, then multiple ascending oral doses over 14 days in Part 2. Dose levels not publicly disclosed. | Oral | Single dose | — |
Development timeline#
- UpcomingPreliminary data from the Phase 2a single-dose crossover study of SYT-510 in generalized anxiety disorder (amygdala fMRI response and defensive-behaviour endpoints), guided for early 2027.↗
- Phase 2a NCT07478744 started (actual start date per ClinicalTrials.gov); Synendos publicly announced the start of dosing on 2026-05-20.
- metPhase 1 SAD/MAD topline in healthy volunteers: no drug-related safety concerns, plasma and CNS exposure at anticipated pharmacological levels, EEG effect consistent with anxiolytic medicines.↗
- Synendos announced EMA authorisation to begin the Phase 1 first-in-human, randomized, double-blind, placebo-controlled single-ascending-dose study of SYT-510 in healthy adults. The SAD study is not registered on ClinicalTrials.gov and its first-dosing date is not disclosed, so this authorisation date is a lower bound for entry into Phase 1.↗
SYT-510 for Generalized anxiety disorder#
Phase 2RecruitingGeneralized anxiety disorder indication →
SYT-510, an oral first-in-class selective endocannabinoid reuptake inhibitor, for generalized anxiety disorder (GAD) — Synendos Therapeutics' lead and only clinical program. After an EMA-authorised first-in-human single-ascending-dose study and a UK multiple-ascending-dose/relative-bioavailability study (NCT06670950, completed May 2025) in healthy volunteers, Synendos reported in September 2025 no drug-related safety concerns, CNS exposure at anticipated pharmacological levels and an EEG signature consistent with anxiolytics. The Phase 2a study NCT07478744 (SYN510CT-GAD201) started 2026-04-22 at South London and Maudsley in collaboration with Professor Allan Young and King's College London: up to 24 adults meeting DSM-5 GAD criteria receive a single oral dose of SYT-510 and placebo in a randomized, quadruple-masked two-way crossover, with primary outcomes of amygdala BOLD fMRI response to fearful stimuli and defensive behaviour on the Joystick Operated Runway Task, plus social avoidance. It is an experimental-medicine proof-of-mechanism study rather than a symptom-scale efficacy trial. The company guides preliminary data for early 2027. No designations are disclosed.
Readouts
- Early 2027AnticipatedTopline dataNCT07478744
Preliminary data from the Phase 2a single-dose crossover study of SYT-510 in generalized anxiety disorder (amygdala fMRI response and defensive-behaviour endpoints), guided for early 2027. ↗
- 2025-09-24ReportedTopline datametNCT06670950
Phase 1 SAD/MAD topline in healthy volunteers: no drug-related safety concerns, plasma and CNS exposure at anticipated pharmacological levels, EEG effect consistent with anxiolytic medicines. ↗
Clinical trials#
NCT07478744SYN510CT-GAD201Phase 2Recruitingn=24
A Phase 2a Efficacy, Safety, Tolerability, and PK Study of SYT-510 in Participants With Generalized Anxiety Disorder
United Kingdom
NCT06670950SYN510CT02Phase 1Completedn=28
A Phase 1 Single Dose and Multiple Ascending Dose Study to Assess the Relative Bioavailability, Food Effect, Safety, Tolerability and Pharmacokinetics of SYT-510 in Healthy Participants
Conference coverage#
SYT-510 appears in 2 CNS Pulse conference abstracts:
- Phase 1 studies assessing safety, tolerability, pharmacokinetics and pharmacodynamics of SYT-510, a first-in-class selective endocannabinoid reuptake inhibitor in healthy volunteers
- Pharmacological characterization of SYT-510, a first-in class selective endocannabinoid reuptake inhibitor and clinical candidate for stress- and anxiety-related disorders[
Sources#
- Maeder C, et al. Pharmacological characterization of SYT-510, a first-in-class selective endocannabinoid reuptake inhibitor. ECNP 2026, PS04-4032 — ECNP Congress 2026 (via CNS Pulse)
- NCT06670950 (SYN510CT02) — A Phase 1 Single Dose and Multiple Ascending Dose Study of SYT-510 in Healthy Participants — ClinicalTrials.gov (U.S. National Library of Medicine)
- NCT07478744 (SYN510CT-GAD201) — A Phase 2a Efficacy, Safety, Tolerability, and PK Study of SYT-510 in Participants With Generalized Anxiety Disorder — ClinicalTrials.gov (U.S. National Library of Medicine)
- Synendos Therapeutics AG Granted EMA Clinical Trial Authorisation for First-in-Class Endocannabinoid System Modulator SYT-510 (2024-01-18, wire copy) — Synendos Therapeutics AG (via MG Magazine)
- Synendos Therapeutics Reports Positive and Highly Promising Topline Results from Phase 1 Trials Paving the Way for Phase 2 in Mental Health (2025-09-24, wire copy) — Synendos Therapeutics AG (via BioSpace)
- Synendos Therapeutics Starts Phase 2 Trial in Generalized Anxiety Disorder (2026-05-20) — Synendos Therapeutics AG